E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Lipoprotein (Lp)(a) has been associated with an increased risk of coronary heart disease, cerebrovascular disease, and peripheral arterial vascular disease. Potential therapies to reduce elevated Lp(a) levels include nicotinic acid (niacin), but there is a lack of randomised controlled studies assessing the effectiveness of these therapies in lowering Lp(a) as a primary endpoint and in reducing cardiovascular events in the long term. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the effect of niacin therapy on mean change in Lp(a) levels to placebo. |
|
E.2.2 | Secondary objectives of the trial |
- To compare the effect of niacin therapy on mean change in plasma lipids levels to placebo - To compare the effect of niacin therapy on mean change in blood glucose levels to placebo. - To compare the effect of niacin therapy on health-related quality of life (Short Form (SF)-12, EQ-5D) - To compare the effect of niacin therapy on cumulative disease-related costs to placebo. - To compare safety and tolerability in patients with niacin therapy and placebo - To compare medication adherence with niacin therapy and placebo.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Lp(a) plasma levels > 30 mg/dl as measured twice - Male or female subjects, aged 18 – 75 years - With and without cardiovascular diseases - Triglyceride levels < 400 mg/dl - Cholesterol and triglyceride levels not requiring immediate change in medication - If concurrent statin therapy, stable doses are required prior and during the study - Willingness to follow all study procedures - Written informed consent |
|
E.4 | Principal exclusion criteria |
- Known hypertriglyceridaemia or fasting triglycerides > 400 mg/dl - Known heterozygous or homozygous familial hypercholesterolaemia or known type III hyperlipoproteinaemia - Documented secondary hypercholesterolaemia of any cause - Initiation or dose change of a lipid-modifying drug within the last four weeks - Known hypersensitivity to nicotinic acid or any components or their derivatives - Concurrent treatment with products containing significant amounts of niacin or nicotinamide - Concurrent treatment with an immediate release formulation of nicotinic acid or a nicotinic acid analogue, e.g. supplements - Cardiovascular diseases which are contra-indicated - Pregnant women, women who are breast feeding, and women of childbearing potential who are not using chemical or mechanical contraception - History of malignancy within preceding 10 years - Use of disallowed concomitant medication - History of alcohol or drug abuse, or both - Active liver disease or hepatic dysfunction - Known uncontrolled or poorly controlled diabetes - Persistent uncontrolled or untreated hypertension - Unexplained serum creatine phosphokinase (CK) >3 times the ULN in the last 4 weeks before the randomisation visit - History of severe myalgia of unknown origin - Arterial bleeding - Active peptic ulcer - Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins - Active gout symptoms - Significant renal insufficiency - Planned hospitalizations for diagnostic or surgical procedures within the next 5 months - Known infectious disease such as hepatitis or HIV - Participation in another investigational drug trial within the four weeks prior to study entry - Previous randomisation into this study - Subjects with serious or unstable medical or psychological condition
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
To evaluate the reduction of cardiovascular events by niacin in patients with elevated Lp(a) levels. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |